Cirrhotic cardiomyopathy prevalence according to the new criteria

Izzy, Manhal; Lin, Grace; Watt, Kymberly D.

doi:10.1111/liv.14826

Cited by 3 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[6] The exclusion of patients because of missing relevant echocardiographic data may have affected the prevalence estimates of CCM in this study; however, the proportion of CCM to no CCM was comparable with what has been reported since the revision of the CCM criteria in 2020. [7,8] In addition, echocardiographic variables such as GLS and IVRT were not available to be assessed in this study as neither of these variables was part of standardof-care echocardiography during the study period. However, the impact of this limitation may be minimal in view of the recent data that showed that impaired GLS is infrequent among patients with end-stage liver disease with a prevalence of <2% and given the limitation of IVRT as a variable influenced by blood pressure, which tends to be low in this patient population.…”

Section: T a B L Ementioning

confidence: 99%

“…Although CCM prevalence according to the original criteria exceeded 50%, the prevalence according to the 2020 criteria appears to be ranging from 28% to 35% among LT candidates, which is still remarkably high. [3,6,7,8] Furthermore, although recent data suggest that the revised criteria predict cardiac outcomes after LT, it is unknown if the original criteria, or some of them, still have utility in predicting cardiac outcomes after LT. [3,7] In this study, we aim to assess the utility of the CCM original criteria and that of the revised criteria in predicting major adverse cardiac events (MACE) after LT.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cirrhotic cardiomyopathy: Appraisal of the original and revised criteria in predicting posttransplant cardiac outcomes

et al. 2022

Self Cite

View full text Add to dashboard Cite

Cardiovascular disease (CVD) significantly contributes to morbidity and mortality after liver transplantation (LT). Cirrhotic cardiomyopathy (CCM) is a risk factor for CVD after transplant. CCM criteria were originally introduced in 2005 with a revision proposed in 2020 reflecting echocardiographic technology advancements. This study assesses the two criteria sets in predicting major adverse cardiac events (MACE) after transplant. This single‐center retrospective study reviewed adult LT recipients between January 1, 2009, and December 31, 2018. Patients with insufficient pre‐LT echocardiographic data, prior ischemic heart disease, portopulmonary hypertension, or longitudinal care elsewhere were excluded. The primary composite outcome was MACE (arrhythmia, heart failure, cardiac arrest, and/or cardiac death) after transplant. Of 1165 patients, 210 met the eligibility criteria. CCM was present in 162 patients (77%) per the original criteria and 64 patients (30%) per the revised criteria. There were 44 MACE and 31 deaths in the study period. Of the deaths, 38.7% occurred secondary to CVD. CCM defined by the original criteria was not associated with MACE after LT (p = 0.21), but the revised definition was significantly associated with MACE (hazard ratio [HR], 1.93; 95% confidence interval, 1.05–3.56; p = 0.04) on multivariable analysis. Echocardiographic variable analysis demonstrated low septal e’ as the most predictive variable for MACE after LT (HR, 3.45; p < 0.001). CCM, only when defined by the revised criteria, was associated with increased risk for MACE after LT, validating the recently revised CCM definition. Abnormal septal e’, reflecting impaired relaxation, appears to be the most predictive echocardiographic criterion for MACE after LT.

show abstract

Section: T a B L Ementioning

confidence: 99%